메뉴 건너뛰기




Volumn 11, Issue 2, 2010, Pages 538-549

Isoxyl aerosols for tuberculosis treatment: Preparation and characterization of particles

Author keywords

Antisolvent precipitation; Multidrug resistant; Pulmonary delivery; Spray drying; Tuberculosis

Indexed keywords

ALCOHOL; MANNITOL; NANOFIBER; NANOPARTICLE; TIOCARLIDE; WATER; AEROSOL; NANOCAPSULE; TUBERCULOSTATIC AGENT;

EID: 77954817188     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-010-9415-y     Document Type: Article
Times cited : (27)

References (47)
  • 3
    • 30444441465 scopus 로고    scopus 로고
    • The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis
    • Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med. 2005;172(12):1487-90.
    • (2005) Am. J. Respir. Crit. Care Med. , vol.172 , Issue.12 , pp. 1487-1490
    • Gelperina, S.1    Kisich, K.2    Iseman, M.D.3    Heifets, L.4
  • 4
    • 0032726452 scopus 로고    scopus 로고
    • Treatment and prevention of multidrug-resistant tuberculosis
    • Bastian I, Colebunders R. Treatment and prevention of multidrug-resistant tuberculosis. Drugs. 1999;58(4):633-61.
    • (1999) Drugs , vol.58 , Issue.4 , pp. 633-661
    • Bastian, I.1    Colebunders, R.2
  • 5
    • 33646822975 scopus 로고    scopus 로고
    • Advances in tuberculosis vaccine strategies
    • Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol. 2006;4(6):469-76.
    • (2006) Nat. Rev. Microbiol. , vol.4 , Issue.6 , pp. 469-476
    • Skeiky, Y.A.1    Sadoff, J.C.2
  • 6
    • 0031901988 scopus 로고    scopus 로고
    • Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients
    • Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest. 1998;113(5):1178-83.
    • (1998) Chest , vol.113 , Issue.5 , pp. 1178-1183
    • Kimerling, M.E.1    Phillips, P.2    Patterson, P.3    Hall, M.4    Robinson, C.A.5    Dunlap, N.E.6
  • 9
    • 70350228508 scopus 로고    scopus 로고
    • Inhaled drug delivery for tuberculosis therapy
    • Muttil P, Wang C, Hickey AJ. Inhaled drug delivery for tuberculosis therapy. Pharm Res. 2009;26:2401-16.
    • (2009) Pharm. Res. , vol.26 , pp. 2401-2416
    • Muttil, P.1    Wang, C.2    Hickey, A.J.3
  • 10
    • 46549090057 scopus 로고    scopus 로고
    • Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan micro-spheres for the treatment of tuberculosis
    • Hwang SM, Kim DD, Chung SJ, Shim CK. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan micro-spheres for the treatment of tuberculosis. J Control Release. 2008;129(2):100-6.
    • (2008) J. Control Release , vol.129 , Issue.2 , pp. 100-106
    • Hwang, S.M.1    Kim, D.D.2    Chung, S.J.3    Shim, C.K.4
  • 11
    • 0037436978 scopus 로고    scopus 로고
    • A novel method for assessing dissolution of aerosol inhaler products
    • Davies NM, Feddah MR. A novel method for assessing dissolution of aerosol inhaler products. Int J Pharm. 2003;255(1-2):175-87.
    • (2003) Int. J. Pharm. , vol.255 , Issue.1-2 , pp. 175-187
    • Davies, N.M.1    Feddah, M.R.2
  • 12
    • 26944439522 scopus 로고    scopus 로고
    • The lungs as a portal of entry for systemic drug delivery
    • Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2004;1(4):338-44.
    • (2004) Proc. Am. Thorac. Soc. , vol.1 , Issue.4 , pp. 338-344
    • Patton, J.S.1    Fishburn, C.S.2    Weers, J.G.3
  • 13
    • 3042545961 scopus 로고    scopus 로고
    • Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: Effects of molecular weight and composition of PLGA on release of rifampicin
    • Makino K, Nakajima T, Shikamura M, Ito F, Ando S, Kochi C et al. Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin. Colloids Surf B Biointerfaces. 2004;36(1):35-42.
    • (2004) Colloids Surf B. Biointerfaces , vol.36 , Issue.1 , pp. 35-42
    • Makino, K.1    Nakajima, T.2    Shikamura, M.3    Ito, F.4    Ando, S.5    Kochi, C.6
  • 15
    • 0013796972 scopus 로고
    • Isoxyl. Tubercle. 1965;46(3):298-300.
    • (1965) Tubercle , vol.46 , Issue.3 , pp. 298-300
    • Isoxyl1
  • 16
    • 0014886149 scopus 로고
    • On the clinical effectiveness of isoxyl
    • Tousek J. On the clinical effectiveness of isoxyl. Antibiot Chemother. 1970;16:149-55.
    • (1970) Antibiot. Chemother. , vol.16 , pp. 149-155
    • Tousek, J.1
  • 17
    • 83955164932 scopus 로고
    • Bartmann K, editor Berlin: Springer-Verlag
    • Bartmann K, editor. Antituberculosis drugs. Berlin: Springer-Verlag; 1988. p. 185-9.
    • (1988) Antituberculosis Drugs , pp. 185-189
  • 19
    • 34547150620 scopus 로고    scopus 로고
    • Preparation of ultrafine beclomethasone dipropionate drug powder by antisolvent precipitation
    • Wang Z, Chen JF, Le Y, Shen ZG, Yun J. Preparation of ultrafine beclomethasone dipropionate drug powder by antisolvent precipitation. Ind Eng Chem Res. 2007;46(14):4839-45.
    • (2007) Ind. Eng. Chem. Res. , vol.46 , Issue.14 , pp. 4839-4845
    • Wang, Z.1    Chen, J.F.2    Le, Y.3    Shen, Z.G.4    Yun, J.5
  • 20
    • 33845906339 scopus 로고    scopus 로고
    • Inhaling medicines: Delivering drugs to the body through the lungs
    • Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67-74.
    • (2007) Nat. Rev. Drug Discov. , vol.6 , Issue.1 , pp. 67-74
    • Patton, J.S.1    Byron, P.R.2
  • 21
    • 47949090122 scopus 로고    scopus 로고
    • Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution
    • Tam JM, McConville JT, Williams 3rd RO, Johnston KP. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. J Pharm Sci. 2008;97:4915-33.
    • (2008) J. Pharm. Sci. , vol.97 , pp. 4915-4933
    • Tam, J.M.1    McConville, J.T.2    Williams III, R.O.3    Johnston, K.P.4
  • 22
    • 0037133126 scopus 로고    scopus 로고
    • Targeting to macrophages: Role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages
    • Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release. 2002;79(1-3):29-40.
    • (2002) J. Control Release , vol.79 , Issue.1-3 , pp. 29-40
    • Ahsan, F.1    Rivas, I.P.2    Khan, M.A.3    Suarez, A.I.T.4
  • 23
    • 0034781469 scopus 로고    scopus 로고
    • Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis
    • Sharma R, Saxena D, Dwivedi AK, Misra A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res. 2001;18(10):1405-10.
    • (2001) Pharm. Res. , vol.18 , Issue.10 , pp. 1405-1410
    • Sharma, R.1    Saxena, D.2    Dwivedi, A.K.3    Misra, A.4
  • 24
    • 34248155773 scopus 로고    scopus 로고
    • Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra
    • Sharma R, Muttil P, Yadav AB, Rath SK, Bajpai VK, Mani U et al. Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra. J Antimicrob Chemother. 2007;59(3):499-506.
    • (2007) J. Antimicrob. Chemother. , vol.59 , Issue.3 , pp. 499-506
    • Sharma, R.1    Muttil, P.2    Yadav, A.B.3    Rath, S.K.4    Bajpai, V.K.5    Mani, U.6
  • 25
    • 47949090122 scopus 로고    scopus 로고
    • Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution
    • Tam JM, McConville JT, Williams 3rd RO, Johnston KP. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. J Pharm Sci. 2008;97(11):4915-33.
    • (2008) J. Pharm. Sci. , vol.97 , Issue.11 , pp. 4915-4933
    • Tam, J.M.1    McConville, J.T.2    Williams III, R.O.3    Johnston, K.P.4
  • 26
    • 33750325780 scopus 로고    scopus 로고
    • Drug nanoparticles by antisolvent precipitation: Mixing energy versus surfactant stabilization
    • Matteucci ME, Hotze MA, Johnston KP, Williams 3rd RO. Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir. 2006;22(21):8951-9.
    • (2006) Langmuir , vol.22 , Issue.21 , pp. 8951-8959
    • Matteucci, M.E.1    Hotze, M.A.2    Johnston, K.P.3    Williams III, R.O.4
  • 27
    • 0004294969 scopus 로고    scopus 로고
    • 4th ed. Oxford: Butterworth-Heinemann
    • Mullin JW. Crystallization. 4th ed. Oxford: Butterworth-Heinemann; 2001.
    • (2001) Crystallization
    • Mullin, J.W.1
  • 29
    • 35248815576 scopus 로고    scopus 로고
    • Antisolvent crystallization of sulfa drugs and the effect of process parameters
    • Park SJ, Yeo SD. Antisolvent crystallization of sulfa drugs and the effect of process parameters. Sep. Sci Technol. 2007;42:2645-60.
    • (2007) Sep. Sci. Technol. , vol.42 , pp. 2645-2660
    • Park, S.J.1    Yeo, S.D.2
  • 30
    • 74049124897 scopus 로고    scopus 로고
    • Spray drying technique. I: Hardware and process parameters
    • Cal K, Sollohub K. Spray drying technique. I: Hardware and process parameters. J Pharm Sci. 2010;99:575-86.
    • (2010) J. Pharm. Sci. , vol.99 , pp. 575-586
    • Cal, K.1    Sollohub, K.2
  • 31
    • 0037433847 scopus 로고    scopus 로고
    • The influence of carrier and drug morphology on drug delivery from dry powder formulations
    • Larhrib H, Martin GP, Marriott C, Prime D. The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int J Pharm. 2003;257(1-2):283-96.
    • (2003) Int. J. Pharm. , vol.257 , Issue.1-2 , pp. 283-296
    • Larhrib, H.1    Martin, G.P.2    Marriott, C.3    Prime, D.4
  • 32
    • 0019846414 scopus 로고
    • Relation of particle dimension to carcinogenicity in amphibole asbestoses and other fibrous minerals
    • Stanton MF, Layard M, Tegeris A, Miller E, May M, Morgan E et al. Relation of particle dimension to carcinogenicity in amphibole asbestoses and other fibrous minerals. J Natl Cancer Inst. 1981;67(5):965-75.
    • (1981) J. Natl. Cancer Inst. , vol.67 , Issue.5 , pp. 965-975
    • Stanton, M.F.1    Layard, M.2    Tegeris, A.3    Miller, E.4    May, M.5    Morgan, E.6
  • 33
    • 0024352294 scopus 로고
    • Multiple mechanisms for the carcinogenic effects of asbestos and other mineral fibers
    • Barrett JC, Lamb PW, Wiseman RW. Multiple mechanisms for the carcinogenic effects of asbestos and other mineral fibers. Environ Health Perspect. 1989;81:81-9.
    • (1989) Environ. Health Perspect. , vol.81 , pp. 81-89
    • Barrett, J.C.1    Lamb, P.W.2    Wiseman, R.W.3
  • 36
    • 67349261427 scopus 로고    scopus 로고
    • Preparation of microsized spherical aggregates of ultrafine ciprofloxacin particles for dry powder inhalation (DPI)
    • Zhao H, Le Y, Liu H, Hu T, Shen Z, Yun J et al. Preparation of microsized spherical aggregates of ultrafine ciprofloxacin particles for dry powder inhalation (DPI). Powder Technol. 2009;194:81-6.
    • (2009) Powder Technol. , vol.194 , pp. 81-86
    • Zhao, H.1    Le, Y.2    Liu, H.3    Hu, T.4    Shen, Z.5    Yun, J.6
  • 37
    • 0016588006 scopus 로고
    • Characterization of habits and crystalline modification of solids and their pharmaceutical applications
    • Haleblian JK. Characterization of habits and crystalline modification of solids and their pharmaceutical applications. J Pharm Sci. 1975;64(8):1269-88.
    • (1975) J. Pharm. Sci. , vol.64 , Issue.8 , pp. 1269-1288
    • Haleblian, J.K.1
  • 38
    • 42049094490 scopus 로고    scopus 로고
    • Pharmaceutical particle engineering via spray drying
    • Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25(5):999-1022.
    • (2008) Pharm. Res. , vol.25 , Issue.5 , pp. 999-1022
    • Vehring, R.1
  • 40
    • 0035937599 scopus 로고    scopus 로고
    • Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future
    • Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3-19.
    • (2001) Adv. Drug Deliv. Rev. , vol.47 , Issue.1 , pp. 3-19
    • Muller, R.H.1    Jacobs, C.2    Kayser, O.3
  • 45
    • 0011489418 scopus 로고    scopus 로고
    • Dispersion and characterization of pharmaceutical dry powder aerosols
    • Dunbar CA, Hickey AJ, Holzner P. Dispersion and characterization of pharmaceutical dry powder aerosols. KONA. 1998;16:7-44.
    • (1998) KONA , vol.16 , pp. 7-44
    • Dunbar, C.A.1    Hickey, A.J.2    Holzner, P.3
  • 47
    • 0342657112 scopus 로고    scopus 로고
    • The influence of carrier morphology on drug delivery by dry powder inhalers
    • Zeng XM, Martin AP, Marriott C, Pritchard J. The influence of carrier morphology on drug delivery by dry powder inhalers. Int J Pharm. 2000;200(1):93-106.
    • (2000) Int. J. Pharm. , vol.200 , Issue.1 , pp. 93-106
    • Zeng, X.M.1    Martin, A.P.2    Marriott, C.3    Pritchard, J.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.